Global Asthma Treatment Drugs

Asthma Treatment Drugs Comprehensive Study by Type (Long-term Control Medications, Quick-relief Medications (Rescue Medications), Medications for Allergy-induced Asthma), Application (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Asthma Medications (Inhaled corticosteroids, Leukotriene modifiers, Long-acting beta agonists (LABAs), Theophylline, Combination inhalers that contain both a corticosteroid and a LABA), End User (Pediatric, Adults, Adolescent) Players and Region - Global Market Outlook to 2028

Asthma Treatment Drugs Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Asthma Treatment Drugs Market Scope
Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. Treatment includes inhaled corticosteroids, leukotriene modifiers, antihistamines and decongestants.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledAstraZeneca (United Kingdom), GlaxoSmithKline (United Kingdom), Teva (Israel), Merck (United Kingdom), Boehringer Ingelheim (Germany), Sanofi (France) BEXIMCO Pharmaceuticals (Bangladesh), Cipla Inc (India), PNEUMA Respiratory (United States), H&T Presspart (United Kingdom) and Pfizer (United Kingdom)
CAGR%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

AstraZeneca (United Kingdom), GlaxoSmithKline (United Kingdom), Teva (Israel), Merck (United Kingdom), Boehringer Ingelheim (Germany), Sanofi (France) BEXIMCO Pharmaceuticals (Bangladesh), Cipla Inc (India), PNEUMA Respiratory (United States), H&T Presspart (United Kingdom) and Pfizer (United Kingdom) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Asthma Treatment Drugs market by Type , by Application (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy) and Region with country level break-up.

On the basis of geography, the market of Asthma Treatment Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2022.

Drug maker Lupin launched Budesonide Inhalation Suspension single-dose ampules, used to treat asthma, in the US market. The company has launched its generic product after receiving the approval from the US Food and Drug Administration (USFDA), Lupin said in a statement. and On 11 August 2020 Drug firm Lupin on it has launched generic Zileuton extended-release tablets - used for the treatment of asthma - in the US market.The product is a generic version of Chiesi USA Inc's Zyflo CR extended-release tablets in the same strength, it added.


Influencing Trend:
Technological Advancements In The Development Of Asthma Drugs

Market Growth Drivers:
Rising Prevalence of Asthma and Favorable Government Initiatives Fuels the Awareness of Asthma Drugs

Challenges:
Government Strict Regulations For The Approval Of Asthma Drugs

Restraints:
Rise In Research & Development Costs In The Pharmaceutical Industries and High Penetration Of Generic Drugs

Opportunities:
Introduction Of Asthma Treatment Drugs In Developing Regions

Key Target Audience
Asthma Treatment Drugs Service Provider, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Report Objectives / Segmentation Covered

By Type
  • Long-term Control Medications
  • Quick-relief Medications (Rescue Medications)
  • Medications for Allergy-induced Asthma
By Application
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
By Asthma Medications
  • Inhaled corticosteroids
  • Leukotriene modifiers
  • Long-acting beta agonists (LABAs)
  • Theophylline
  • Combination inhalers that contain both a corticosteroid and a LABA

By End User
  • Pediatric
  • Adults
  • Adolescent

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Asthma
      • 3.2.2. Favorable Government Initiatives Fuels the Awareness of Asthma Drugs
    • 3.3. Market Challenges
      • 3.3.1. Government Strict Regulations For The Approval Of Asthma Drugs
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements In The Development Of Asthma Drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Asthma Treatment Drugs, by Type, Application, Asthma Medications, End User and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Asthma Treatment Drugs (Value)
      • 5.2.1. Global Asthma Treatment Drugs by: Type (Value)
        • 5.2.1.1. Long-term Control Medications
        • 5.2.1.2. Quick-relief Medications (Rescue Medications)
        • 5.2.1.3. Medications for Allergy-induced Asthma
      • 5.2.2. Global Asthma Treatment Drugs by: Application (Value)
        • 5.2.2.1. Hospital Pharmacy
        • 5.2.2.2. Retail Pharmacy
        • 5.2.2.3. Online Pharmacy
      • 5.2.3. Global Asthma Treatment Drugs by: Asthma Medications (Value)
        • 5.2.3.1. Inhaled corticosteroids
        • 5.2.3.2. Leukotriene modifiers
        • 5.2.3.3. Long-acting beta agonists (LABAs)
        • 5.2.3.4. Theophylline
        • 5.2.3.5. Combination inhalers that contain both a corticosteroid and a LABA
      • 5.2.4. Global Asthma Treatment Drugs by: End User (Value)
        • 5.2.4.1. Pediatric
        • 5.2.4.2. Adults
        • 5.2.4.3. Adolescent
      • 5.2.5. Global Asthma Treatment Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Asthma Treatment Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Boehringer Ingelheim (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi (France) BEXIMCO Pharmaceuticals (Bangladesh)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cipla Inc (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. PNEUMA Respiratory (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. H&T Presspart (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Asthma Treatment Drugs Sale, by Type, Application, Asthma Medications, End User and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Asthma Treatment Drugs (Value)
      • 7.2.1. Global Asthma Treatment Drugs by: Type (Value)
        • 7.2.1.1. Long-term Control Medications
        • 7.2.1.2. Quick-relief Medications (Rescue Medications)
        • 7.2.1.3. Medications for Allergy-induced Asthma
      • 7.2.2. Global Asthma Treatment Drugs by: Application (Value)
        • 7.2.2.1. Hospital Pharmacy
        • 7.2.2.2. Retail Pharmacy
        • 7.2.2.3. Online Pharmacy
      • 7.2.3. Global Asthma Treatment Drugs by: Asthma Medications (Value)
        • 7.2.3.1. Inhaled corticosteroids
        • 7.2.3.2. Leukotriene modifiers
        • 7.2.3.3. Long-acting beta agonists (LABAs)
        • 7.2.3.4. Theophylline
        • 7.2.3.5. Combination inhalers that contain both a corticosteroid and a LABA
      • 7.2.4. Global Asthma Treatment Drugs by: End User (Value)
        • 7.2.4.1. Pediatric
        • 7.2.4.2. Adults
        • 7.2.4.3. Adolescent
      • 7.2.5. Global Asthma Treatment Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Asthma Treatment Drugs: by Type(USD Million)
  • Table 2. Asthma Treatment Drugs Long-term Control Medications , by Region USD Million (2017-2022)
  • Table 3. Asthma Treatment Drugs Quick-relief Medications (Rescue Medications) , by Region USD Million (2017-2022)
  • Table 4. Asthma Treatment Drugs Medications for Allergy-induced Asthma , by Region USD Million (2017-2022)
  • Table 5. Asthma Treatment Drugs: by Application(USD Million)
  • Table 6. Asthma Treatment Drugs Hospital Pharmacy , by Region USD Million (2017-2022)
  • Table 7. Asthma Treatment Drugs Retail Pharmacy , by Region USD Million (2017-2022)
  • Table 8. Asthma Treatment Drugs Online Pharmacy , by Region USD Million (2017-2022)
  • Table 9. Asthma Treatment Drugs: by Asthma Medications(USD Million)
  • Table 10. Asthma Treatment Drugs Inhaled corticosteroids , by Region USD Million (2017-2022)
  • Table 11. Asthma Treatment Drugs Leukotriene modifiers , by Region USD Million (2017-2022)
  • Table 12. Asthma Treatment Drugs Long-acting beta agonists (LABAs) , by Region USD Million (2017-2022)
  • Table 13. Asthma Treatment Drugs Theophylline , by Region USD Million (2017-2022)
  • Table 14. Asthma Treatment Drugs Combination inhalers that contain both a corticosteroid and a LABA , by Region USD Million (2017-2022)
  • Table 15. Asthma Treatment Drugs: by End User(USD Million)
  • Table 16. Asthma Treatment Drugs Pediatric , by Region USD Million (2017-2022)
  • Table 17. Asthma Treatment Drugs Adults , by Region USD Million (2017-2022)
  • Table 18. Asthma Treatment Drugs Adolescent , by Region USD Million (2017-2022)
  • Table 19. South America Asthma Treatment Drugs, by Country USD Million (2017-2022)
  • Table 20. South America Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 21. South America Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 22. South America Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 23. South America Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 24. Brazil Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 25. Brazil Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 26. Brazil Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 27. Brazil Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 28. Argentina Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 29. Argentina Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 30. Argentina Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 31. Argentina Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 32. Rest of South America Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 33. Rest of South America Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 34. Rest of South America Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 35. Rest of South America Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 36. Asia Pacific Asthma Treatment Drugs, by Country USD Million (2017-2022)
  • Table 37. Asia Pacific Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 38. Asia Pacific Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 39. Asia Pacific Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 40. Asia Pacific Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 41. China Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 42. China Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 43. China Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 44. China Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 45. Japan Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 46. Japan Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 47. Japan Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 48. Japan Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 49. India Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 50. India Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 51. India Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 52. India Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 53. South Korea Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 54. South Korea Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 55. South Korea Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 56. South Korea Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 57. Taiwan Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 58. Taiwan Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 59. Taiwan Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 60. Taiwan Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 61. Australia Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 62. Australia Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 63. Australia Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 64. Australia Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 68. Rest of Asia-Pacific Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 69. Europe Asthma Treatment Drugs, by Country USD Million (2017-2022)
  • Table 70. Europe Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 71. Europe Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 72. Europe Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 73. Europe Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 74. Germany Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 75. Germany Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 76. Germany Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 77. Germany Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 78. France Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 79. France Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 80. France Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 81. France Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 82. Italy Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 83. Italy Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 84. Italy Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 85. Italy Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 86. United Kingdom Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 87. United Kingdom Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 88. United Kingdom Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 89. United Kingdom Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 90. Netherlands Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 91. Netherlands Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 92. Netherlands Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 93. Netherlands Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 94. Rest of Europe Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 95. Rest of Europe Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 96. Rest of Europe Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 97. Rest of Europe Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 98. MEA Asthma Treatment Drugs, by Country USD Million (2017-2022)
  • Table 99. MEA Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 100. MEA Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 101. MEA Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 102. MEA Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 103. Middle East Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 104. Middle East Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 105. Middle East Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 106. Middle East Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 107. Africa Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 108. Africa Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 109. Africa Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 110. Africa Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 111. North America Asthma Treatment Drugs, by Country USD Million (2017-2022)
  • Table 112. North America Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 113. North America Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 114. North America Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 115. North America Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 116. United States Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 117. United States Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 118. United States Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 119. United States Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 120. Canada Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 121. Canada Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 122. Canada Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 123. Canada Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 124. Mexico Asthma Treatment Drugs, by Type USD Million (2017-2022)
  • Table 125. Mexico Asthma Treatment Drugs, by Application USD Million (2017-2022)
  • Table 126. Mexico Asthma Treatment Drugs, by Asthma Medications USD Million (2017-2022)
  • Table 127. Mexico Asthma Treatment Drugs, by End User USD Million (2017-2022)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Asthma Treatment Drugs: by Type(USD Million)
  • Table 139. Asthma Treatment Drugs Long-term Control Medications , by Region USD Million (2023-2028)
  • Table 140. Asthma Treatment Drugs Quick-relief Medications (Rescue Medications) , by Region USD Million (2023-2028)
  • Table 141. Asthma Treatment Drugs Medications for Allergy-induced Asthma , by Region USD Million (2023-2028)
  • Table 142. Asthma Treatment Drugs: by Application(USD Million)
  • Table 143. Asthma Treatment Drugs Hospital Pharmacy , by Region USD Million (2023-2028)
  • Table 144. Asthma Treatment Drugs Retail Pharmacy , by Region USD Million (2023-2028)
  • Table 145. Asthma Treatment Drugs Online Pharmacy , by Region USD Million (2023-2028)
  • Table 146. Asthma Treatment Drugs: by Asthma Medications(USD Million)
  • Table 147. Asthma Treatment Drugs Inhaled corticosteroids , by Region USD Million (2023-2028)
  • Table 148. Asthma Treatment Drugs Leukotriene modifiers , by Region USD Million (2023-2028)
  • Table 149. Asthma Treatment Drugs Long-acting beta agonists (LABAs) , by Region USD Million (2023-2028)
  • Table 150. Asthma Treatment Drugs Theophylline , by Region USD Million (2023-2028)
  • Table 151. Asthma Treatment Drugs Combination inhalers that contain both a corticosteroid and a LABA , by Region USD Million (2023-2028)
  • Table 152. Asthma Treatment Drugs: by End User(USD Million)
  • Table 153. Asthma Treatment Drugs Pediatric , by Region USD Million (2023-2028)
  • Table 154. Asthma Treatment Drugs Adults , by Region USD Million (2023-2028)
  • Table 155. Asthma Treatment Drugs Adolescent , by Region USD Million (2023-2028)
  • Table 156. South America Asthma Treatment Drugs, by Country USD Million (2023-2028)
  • Table 157. South America Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 158. South America Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 159. South America Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 160. South America Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 161. Brazil Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 162. Brazil Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 163. Brazil Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 164. Brazil Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 165. Argentina Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 166. Argentina Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 167. Argentina Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 168. Argentina Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 169. Rest of South America Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 170. Rest of South America Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 171. Rest of South America Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 172. Rest of South America Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 173. Asia Pacific Asthma Treatment Drugs, by Country USD Million (2023-2028)
  • Table 174. Asia Pacific Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 175. Asia Pacific Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 176. Asia Pacific Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 177. Asia Pacific Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 178. China Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 179. China Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 180. China Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 181. China Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 182. Japan Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 183. Japan Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 184. Japan Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 185. Japan Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 186. India Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 187. India Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 188. India Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 189. India Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 190. South Korea Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 191. South Korea Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 192. South Korea Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 193. South Korea Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 194. Taiwan Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 195. Taiwan Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 196. Taiwan Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 197. Taiwan Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 198. Australia Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 199. Australia Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 200. Australia Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 201. Australia Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 202. Rest of Asia-Pacific Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 203. Rest of Asia-Pacific Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 204. Rest of Asia-Pacific Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 205. Rest of Asia-Pacific Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 206. Europe Asthma Treatment Drugs, by Country USD Million (2023-2028)
  • Table 207. Europe Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 208. Europe Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 209. Europe Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 210. Europe Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 211. Germany Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 212. Germany Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 213. Germany Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 214. Germany Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 215. France Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 216. France Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 217. France Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 218. France Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 219. Italy Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 220. Italy Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 221. Italy Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 222. Italy Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 223. United Kingdom Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 224. United Kingdom Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 225. United Kingdom Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 226. United Kingdom Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 227. Netherlands Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 228. Netherlands Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 229. Netherlands Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 230. Netherlands Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 231. Rest of Europe Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 232. Rest of Europe Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 233. Rest of Europe Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 234. Rest of Europe Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 235. MEA Asthma Treatment Drugs, by Country USD Million (2023-2028)
  • Table 236. MEA Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 237. MEA Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 238. MEA Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 239. MEA Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 240. Middle East Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 241. Middle East Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 242. Middle East Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 243. Middle East Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 244. Africa Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 245. Africa Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 246. Africa Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 247. Africa Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 248. North America Asthma Treatment Drugs, by Country USD Million (2023-2028)
  • Table 249. North America Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 250. North America Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 251. North America Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 252. North America Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 253. United States Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 254. United States Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 255. United States Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 256. United States Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 257. Canada Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 258. Canada Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 259. Canada Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 260. Canada Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 261. Mexico Asthma Treatment Drugs, by Type USD Million (2023-2028)
  • Table 262. Mexico Asthma Treatment Drugs, by Application USD Million (2023-2028)
  • Table 263. Mexico Asthma Treatment Drugs, by Asthma Medications USD Million (2023-2028)
  • Table 264. Mexico Asthma Treatment Drugs, by End User USD Million (2023-2028)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Asthma Treatment Drugs: by Type USD Million (2017-2022)
  • Figure 5. Global Asthma Treatment Drugs: by Application USD Million (2017-2022)
  • Figure 6. Global Asthma Treatment Drugs: by Asthma Medications USD Million (2017-2022)
  • Figure 7. Global Asthma Treatment Drugs: by End User USD Million (2017-2022)
  • Figure 8. South America Asthma Treatment Drugs Share (%), by Country
  • Figure 9. Asia Pacific Asthma Treatment Drugs Share (%), by Country
  • Figure 10. Europe Asthma Treatment Drugs Share (%), by Country
  • Figure 11. MEA Asthma Treatment Drugs Share (%), by Country
  • Figure 12. North America Asthma Treatment Drugs Share (%), by Country
  • Figure 13. Global Asthma Treatment Drugs share by Players 2022 (%)
  • Figure 14. Global Asthma Treatment Drugs share by Players (Top 3) 2022(%)
  • Figure 15. Global Asthma Treatment Drugs share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. AstraZeneca (United Kingdom) Revenue: by Geography 2022
  • Figure 19. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2022
  • Figure 21. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 22. Teva (Israel) Revenue: by Geography 2022
  • Figure 23. Merck (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. Merck (United Kingdom) Revenue: by Geography 2022
  • Figure 25. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Boehringer Ingelheim (Germany) Revenue: by Geography 2022
  • Figure 27. Sanofi (France) BEXIMCO Pharmaceuticals (Bangladesh) Revenue, Net Income and Gross profit
  • Figure 28. Sanofi (France) BEXIMCO Pharmaceuticals (Bangladesh) Revenue: by Geography 2022
  • Figure 29. Cipla Inc (India) Revenue, Net Income and Gross profit
  • Figure 30. Cipla Inc (India) Revenue: by Geography 2022
  • Figure 31. PNEUMA Respiratory (United States) Revenue, Net Income and Gross profit
  • Figure 32. PNEUMA Respiratory (United States) Revenue: by Geography 2022
  • Figure 33. H&T Presspart (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. H&T Presspart (United Kingdom) Revenue: by Geography 2022
  • Figure 35. Pfizer (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. Pfizer (United Kingdom) Revenue: by Geography 2022
  • Figure 37. Global Asthma Treatment Drugs: by Type USD Million (2023-2028)
  • Figure 38. Global Asthma Treatment Drugs: by Application USD Million (2023-2028)
  • Figure 39. Global Asthma Treatment Drugs: by Asthma Medications USD Million (2023-2028)
  • Figure 40. Global Asthma Treatment Drugs: by End User USD Million (2023-2028)
  • Figure 41. South America Asthma Treatment Drugs Share (%), by Country
  • Figure 42. Asia Pacific Asthma Treatment Drugs Share (%), by Country
  • Figure 43. Europe Asthma Treatment Drugs Share (%), by Country
  • Figure 44. MEA Asthma Treatment Drugs Share (%), by Country
  • Figure 45. North America Asthma Treatment Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AstraZeneca (United Kingdom)
  • GlaxoSmithKline (United Kingdom)
  • Teva (Israel)
  • Merck (United Kingdom)
  • Boehringer Ingelheim (Germany)
  • Sanofi (France) BEXIMCO Pharmaceuticals (Bangladesh)
  • Cipla Inc (India)
  • PNEUMA Respiratory (United States)
  • H&T Presspart (United Kingdom)
  • Pfizer (United Kingdom)
Select User Access Type

Key Highlights of Report


Jul 2023 224 Pages 68 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Asthma Treatment Drugs Quantitative research analysis
Global Asthma Treatment Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Asthma Treatment Drugs Market are by type [Long-term Control Medications, Quick-relief Medications (Rescue Medications) and Medications for Allergy-induced Asthma], by end use application [Hospital Pharmacy, Retail Pharmacy and Online Pharmacy].
The Asthma Treatment Drugs Market is gaining popularity and expected to see strong valuation by 2028.
  • Rising Prevalence of Asthma
  • Favorable Government Initiatives Fuels the Awareness of Asthma Drugs

Know More About Global Asthma Treatment Drugs Report?

Have a Query? Click Here

Other Related Reports

Nevirapine Comprehensive Study by Type (100 mg, 200 mg, 400 mg), Application (Women (Pregnant, Non- pregnant), Men), Method (Antiretroviral Therapy, Hepatotoxicity) Players and Region - Global Market...
$ 3500
Medication Adherence Packaging Systems Comprehensive Study by Type (Unit-dose Packaging Systems, Multi-dose Packaging Systems), Packaging (Ampoules, Vials, Prefilled Syringes & Injectable, Blisters, ...
$ 3750
Osteoarthritis Pain Drugs Comprehensive Study by Type (Oral, Injection, External), Application (Medical Care, Personal Care), Therapies (Non- Pharmacological Therapy, Pharmacological Therapy, Surgica...
$ 3750
Docusate Sodium Comprehensive Study by Type (DSS 100%, DSS 85%, DSS 50%), Application (Exicipient, Active Pharmaceutical Ingredients, Constipation, Pesticide adjuvant, Micelle encapsulation), Route o...
$ 3650
Resistant Maltodextrin Comprehensive Study by Type (Corn-based, Wheat-based, Others), Application (Beverages, Bakery & Confectionery, Dairy Products, Nutraceuticals, Others) Players and Region - Glob...
$ 3500
Lansoprazole Comprehensive Study by Type (Capsules, OD Tablet, Injection), Application (Male, Female), Distribution Channel (Hospital pharmacies, Online pharmacies, Retail pharmacies, Drug stores), R...
$ 3350